Introduction {#s1}
============

Curative surgery remains the mainstay of treatment for hepatocellular carcinoma (HCC) in patients with non-metastasized tumors. Recurrence of the neoplasm following the curative hepatectomy can greatly impact the long-term prognosis of those HCC patients. The clinicopathologic risk factors of tumor size, tumor number, vascular invasion and tumor-node-metastasis (TNM) staging have been shown to be associated with the poor clinical outcomes \[[@R01]-[@R03]\]; however, the validation of such potential biomarkers for prognosis is still needed.

Arginase-1 is an enzyme that is responsible for the conversion of arginine to urea in the urea cycle and it is highly expressed in benign and malignant hepatocytes, especially those located around the periportal regions \[[@R04], [@R05]\]. Compared to other hepatocytic markers, arginase-1 is a highly sensitive and specific marker of hepatocellular differentiation \[[@R06], [@R07]\]. The prognostic value of arginase-1 has only been analyzed in one study to date. Mao and colleagues \[[@R08]\] showed that high arginase-1 expression was associated with better recurrence-free and overall survival; however, their stratification of patients into high and low arginase expression was not clearly elucidated, since 98% of all the HCC tumors examined expressed arginase-1.

In the fetal liver, hepatic stem cells give rise to hepatoblasts, which differentiate into the hepatocytic and biliary lineages. Prior to this differentiation, overexpression of cytokeratin 19 (CK19) is observed in the hepatic progenitor cells \[[@R9], [@R10]\]. CK19 expression decreases in cells committed to the hepatocytic pathway, whereas the expression is retained in the cholangiocytes \[[@R9], [@R11]\]. Although it is well accepted that CK19 is a biomarker of cholangiocarcinoma, its overexpression has been observed in HCC of hepatic stem cell origin and found to be associated with poor prognosis \[[@R12]-[@R14]\].

Previous studies have evaluated the prognostic importance of arginase expression or CK19 expression in HCC patients. Combined detection of both markers has never been evaluated. In this study, we first validated arginase-1 expression in HCC tissues by using a highly specific monoclonal antibody and then we explored the predictive value of arginase-1 and CK19 combined expression for the prognosis of HCC following curative surgery.

Materials and Methods {#s2}
=====================

Patients and tissue specimens {#s2a}
-----------------------------

One hundred twelve patients who underwent curative hepatectomy for HCC at our institution between January 2013 and January 2016 were included. The inclusion criteria identified patients: 1) with histologic diagnosis of HCC; 2) who underwent curative surgery with no presurgical treatment resulting in tissue necrosis; 3) who had formalin-fixed paraffin-embedded tissue samples; 4) with no concurrent presence of another liver carcinoma; and 5) with complete clinicopathologic and follow-up information. Two hundred fifteen patients were initially identified, but 103 of these were excluded due to either previous treatment, concurrent carcinoma (i.e. hepatocholangiocarcinoma) or incomplete follow-up data.

Ages of the 112 total included patients ranged from 16 to 83 years (median: 65 years). Eighty-one (72.3%) males and 31 (27.7%) females were included. Hepatitis C virus was detected in 61 patients (54.5%), and hepatitis B infection was found in 20 patients (17.8%). Liver cirrhosis was present in 72 patients (64.3%).

Serum alpha-fetoprotein (AFP) level had been measured prior to surgery. The tumor size, tumor number, tumor grade and presence of vascular invasion were determined by postoperative pathological examination. The TNM staging was carried out according to the seventh edition system \[[@R15]\]. For all patients, the postoperative follow-up schedule consisted of imaging and AFP level screening at every 3 months for the first 6 months, followed by a 12-month interval thereafter. Diagnosis of recurrence was based on typical imaging appearance in computed tomography and/or magnetic resonance imaging scan with/without an elevated serum AFP level. The data for overall survival and recurrence covered the range of time from each patient's hepatic resection to death or the last clinical observation, respectively. The median follow-up period was 33 months (range: 1 - 67 months).

The clinicopathologic features of the patients in our study population are summarized in [Table 1](#T1){ref-type="table"}. The study was approved by the Georgetown University Institutional Review Board.

###### Associations of Arginase-1/CK19 Expression and Clinicopathologic Parameters in HCC

  Variables           n    Arginase-1   CK19                     
  ------------------- ---- ------------ ------ ------- ---- ---- -------
  Age                                          0.617             0.617
    ≥ 65              57   46           11             11   46   
    \< 65             55   47           8              8    47   
  Sex                                          0.16              0.779
    Male              81   70           11             13   68   
    Female            31   23           8              6    25   
  HBV                                          0.022             0.103
    Present           20   20           0              6    14   
    Absent            92   73           19             13   79   
  HCV                                          1                 0.615
    Present           61   51           10             9    52   
    Absent            51   42           9              10   41   
  AFP                                          0.217             0.083
    Low               62   54           8              7    55   
    High              50   39           11             12   38   
  Cirrhosis                                    0.602             1
    Present           72   61           11             12   60   
    Absent            40   32           8              7    33   
  Tumor size                                                     
    ≥ 5 cm            29   21           8      0.089   5    24   1
    \< 5 cm           83   72           11             14   69   
  Tumor number                                 0.29              0.598
    Solitary          73   63           10             11   62   
    Multiple          39   30           9              8    31   
  Grade                                        0.309             0.077
    I-II              68   54           14             8    60   
    III-IV            44   39           5              11   33   
  Vascular invasion                            0.044             0.273
    Present           30   21           9              7    23   
    Absent            82   72           10             12   70   
  TNM stage                                    0.009             1
    I-II              95   83           12             16   79   
    III-IV            17   10           7              3    14   

HCC: hepatocellular carcinoma; n: number; HBV: hepatitis B virus; HCV: hepatitis C virus; TNM: tumor-node-metastasis; AFP: alpha-fetoprotein; CK19: cytokeratin 19.

Immunohistochemical evaluation {#s2b}
------------------------------

Sections (4 µm thick) of the formalin-fixed, paraffin-embedded tissue blocks of all the studied cases (a single HCC sample per patient) were investigated by specific antibody reactivity for the expression of arginase-1 (dilution 1:4,000, clone SL6ARG; Invitrogen, San Diego, CA, USA) and CK19 (ready-to-use, clone RCK108; Dako, Glostrup, Denmark) using an automated method (Dako enVision + dual link system-horseradish peroxidase). Pretreatment of the formalin-fixed, paraffin-embedded tissue sections with heat-induced epitope retrieval was performed using diluted enVision Flex target retrieval solution, low pH (× 50) (K8004; Dako).

Deparaffinization, rehydration and epitope retrieval were performed by the Dako PT link pretreatment system (PT100/PT101) using the following parameters: preheat temperature: 85 °C; epitope retrieval temperature and time: 97 °C for 20 min and cool-down to 65 °C. Racks were placed in diluted enVision Flex wash buffer (× 20) (K8007; Dako) for 5 min. The slides were then treated with Flex peroxidase blocking solution (SM801; Dako) for 5 min, followed by incubation with the primary antibodies (arginase-1 or CK19) for 20 min. The slides were next treated sequentially with Flex mouse linker (SM804; Dako) for 15 min, Flex horseradish peroxidase (SM802; Dako) for 20 min, and Flex diaminobenzidine with substrate-chromogen (SM803; Dako) for 10 min. Sections were counterstained with hematoxylin for 5 min before assessment under microscope.

Patient-matched normal (adjacent benign) liver tissues served as the positive control and normal (adjacent benign) bile duct epithelium served as an internal positive control for CK19 (both processed as described above). The negative control was generated by identical treatment of each patient's experimental tissue but omitting the primary antibody. A positive result for arginase-1 expression was indicated by cytoplasmic staining with or without nuclear staining in the tumor cells. The extent of positive tumor cells was classified as 1 (focal; when ≤ 50% of the tumor cells were positive), 2 (regional; when 50-90% of the tumor cells were positive), and 3 (diffuse; when ≥ 90% of the tumor cells were positive). The intensity of immunostaining was scored as 0 (negative/weak staining), 1+ (moderate staining), and 2+ (intense staining). The extent and intensity tumor scores were multiplied to give a composite score (range: 0 - 6) for each tissue specimen. Composite scores of 0 - 3 were described as having low arginase-1 expression, and scores of 4 - 6 were defined as high arginase-1 expression. CK19 expression was considered positive if moderate or intense staining was present in ≥ 5% of the tumor cells \[[@R12]\]. Immunoreactivity was semi-quantitatively scored by two pathologists.

Statistical analysis {#s2c}
--------------------

The relationships between arginase-1 and CK19 expressions and the various clinicopathologic characteristics were determined using Fisher's exact test. Comparisons of recurrence-free and overall survival were performed by the log-rank test. Cox proportional hazards models were used in univariate and multivariate regression analyses. To control for stage, we stratified the patients into stage III/IV versus stage I/II, and compared survival within each group. We controlled for vascular invasion in the same way. The statistical computing language R 3.4.4 (The R Foundation, Vienna, Austria) was adopted for all the analyses. The statistical significance of the analyses was confirmed when a P value was less than 0.05.

Results {#s3}
=======

Immunostaining pattern of arginase-1 and CK19 {#s3a}
---------------------------------------------

In sections of HCC, arginase-1 positivity was demonstrated with cytoplasmic staining with or without nuclear staining within the tumor cells ([Fig. 1a](#F1){ref-type="fig"}). Arginase-1 was highly expressed in 93 of the HCCs (83%), showing immunostaining in 80-100% of those tumors. Of the 19 HCCs with low arginase-1 expression, eight (7.1%) showed negative staining for the protein ([Fig. 1b](#F1){ref-type="fig"}), while the remaining patients had weak expression of arginase-1 (in \< 15% of the tumor cells). Sections of adjacent benign liver demonstrated intense and diffuse staining in all the hepatocytes ([Fig. 1c](#F1){ref-type="fig"}). CK19 expression was positive in the cytoplasm and membranes of hepatocytes in 19 HCCs (17%) ([Fig. 1d](#F1){ref-type="fig"}); all other HCCs were negative for CK19 ([Fig. 1e](#F1){ref-type="fig"}). In addition, positive CK19 staining was observed in the positive control normal (adjacent benign bile duct epithelium) tissue ([Fig. 1f](#F1){ref-type="fig"}).

![Expression of arginase-1 and CK19 in HCC. (a) High arginase-1 expression (× 200). (b) Low arginase-1 expression (× 200). (c) Arginase-1 is highly expressed in adjacent benign liver (× 12.5). (d) Positive CK19 expression (× 200). (e) Negative CK19 expression (× 200). (f) CK19 expression in adjacent benign bile duct epithelium (× 200). CK19: cytokeratin 19; HCC: hepatocellular carcinoma.](gr-12-078-g001){#F1}

Clinicopathologic significance of arginase-1 and CK19 {#s3b}
-----------------------------------------------------

[Table 1](#T1){ref-type="table"} shows the statistical (positive) correlation of arginase-1 expression with hepatitis B viral infection (P = 0.02), vascular invasion (P = 0.044), and TNM stage (P = 0.009). CK19 expression was not associated with any clinicopathologic variable. Other parameters, including tumor grade, tumor number, tumor size, presence of cirrhosis, serum AFP level, hepatitis C viral infection, age and sex showed no significant correlation with arginase-1 or CK19 expression.

Prognostic significance of arginase-1 and CK19 {#s3c}
----------------------------------------------

In the univariate analyses ([Table 2](#T2){ref-type="table"}), the clinicopathologic parameters of serum AFP level, tumor grade, vascular invasion and TNM stage were all statistically significant for adverse recurrence-free and overall survival (all, P \< 0.05). CK19 expression in HCC was associated with decreased recurrence-free survival when compared with CK19-negative HCC (P = 0.001), while arginase-1 expression was not ([Fig. 2](#F2){ref-type="fig"}). The combination of arginase-1 and CK19 expressions more significantly discriminated poor patient prognosis than either marker alone (P = 0.0008).

###### Univariate Predictors for RFS and OS in Patients With HCC

  Variables                  n     RFS       OS                                                  
  -------------------------- ----- --------- ---------------- --------- ------- ---------------- --------
  Age                                                         0.816                              0.371
    ≥ 65                     57    1.079     0.786 - 0.57               1.534   0.594 - 3.96     
    \< 65                    76    1                                    1                        
  Sex                                                         0.562                              0.517
    Male                     81    1.244     0.587 - 2.637              1.428   0.47 - 4.34      
    Female                   31    1                                    1                        
  HBV                                                         0.258                              0.905
    Yes                      20    1.573     0.74 - 3.346               0.928   0.2686 - 3.207   
    No                       92    1                                    1                        
  HCV                                                         0.065                              0.273
    Yes                      61    0.543     0.283 - 1.043              0.594   0.233 - 1.512    
    No                       51    1                                    1                        
  AFP                                                         0.004                              0.009
    High                     50    2.639     1.341 - 5.194              3.617   1.288 - 10.15    
    Low                      62    1                                    1                        
  Cirrhosis                                                   0.052                              0.446
    Yes                      72    0.524     0.275 - 0.999              0.694   0.275 - 1.759    
    No                       40    1                                    1                        
  Tumor size                                                  0.282                              0.200
    ≥ 5 cm                   29    1.471     0.741 - 2.919              1.893   0.733 - 4.339    
    \< 5 cm                  83    1                                    1                        
  TN                                                          0.939                              0.884
    Multiple                 39    1.027     0.974 - 0.523              0.93    0.349 - 2.48     
    Solitary                 73    1                                    1                        
  VI                                                          0.0001                             0.0007
    Yes                      30    3.675     1.906 - 7.088              5.142   1.987 - 13.31    
    No                       82    1                                    1                        
  Grade                                                       0.00008                            0.0002
    I-II                     68    1                                    1                        
    III-IV                   44    3.694     1.897 - 7.196              6.538   2.145 - 19.93    
  TNM stage                                                   0.001                              0.01
    I-II                     95    1                                    1                        
    III-IV                   17    3.547     1.765 - 7.129              3.574   1.378 - 9.265    
  Arginase                                                    0.185                              0.142
    High                     93    1.904     0.675 - 5.369              3.489   0.464 - 26.23    
    Low                      19    1                                    1                        
  CK19                                                        0.0002                             0.945
    Positive                 19    4.093     2.059 - 8.136              1.03    0.277 - 3.308    
    Negative                 93    1                                    1                        
  Arg-1/CK19                                                  0.00008                            0.963
    High/positive            17    4.71      2.31 - 9.162               1.342   0.298 - 3.56     
    Others                   95    1                                    1                        
  Arg-1/CK19/TN                                               0.02                               0.884
    High/positive/multiple   7     3.556     1.371 - 9.221              0.93    0.349 - 2.479    
    Others                   105   1                                    1                        
  Arg-1/CK19/TNM stage                       0.01                               0.242            
    High/positive/III/IV     7     4.815     0.687 - 13.74              2.706   0.62 - 11.805    
    Others                   105   1                                    1                        
  Arg-1/CK19/VI                    0.00008                              0.082                    
    High/positive/present    5     8.061     3.449 - 18.841             3.5     1.033 - 12.36    
    Others                   107   1                                    1                        
  Arg-1/TNM stage                                             0.02                               0.028
    High                     93    2.881     0.99 - 8.382               6.091   0.778 - 47.7     
    Low                      19    1                                    1                        
  Arg-1/stage III-IV                                          0.03                               0.272
    High                     10    4.394     0.925 - 20.87              2.93    0.343 - 25.167   
    Low                      7     1                                    1                        
  CK19/stage III-IV                                           0.338                              0.972
    Positive                 3     1.847     0.55 - 6.191               0.962   0.111 - 8.322    
    Negative                 14    1                                    1                        
  Arg-1/VI                                                    0.04                               0.072
    High                     21    3.072     0.881 - 10.705             4.659   0.595 - 36.4     
    Low                      9     1                                    1                        
  CK19/VI                                                     0.007                              0.744
    Positive                 7     4.295     1.591 - 11.594             1.253   0.330 - 4.747    
    Negative                 12    1                                    1                        

HCC: hepatocellular carcinoma; OS: overall survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; VI: vascular invasion; TN: tumor number; TNM: tumor-node-metastasis; AFP: alpha-fetoprotein; Arg-1: arginase-1; CK19: cytokeratin 19.

![Prognostic significance of arginase-1 and CK19. Comparisons of recurrence-free survival and overall survival by CK19 (a, b), arginase-1 (c, d), and arginase-1/CK19 (e, f). CK19: cytokeratin 19.](gr-12-078-g002){#F2}

Stratification of arginase-1 expression over the various TNM stages demonstrated that patients with high arginase-1 expression and advanced TNM stage were associated with lower recurrence-free survival (P = 0.03), whereas the combination of CK19 expression and advanced TNM stage was not. Similarly, patients with high arginase-1 (P = 0.04) or CK19 (P = 0.007) expression and vascular invasion were negatively associated with recurrence-free survival. High arginase-1 and CK19 expressions in addition to either TNM stage (P = 0.01), multiple tumors (P = 0.02) or vascular invasion (P = 0.0008) significantly correlated with lower recurrence-free survival. However, neither arginase-1 nor CK19 was significantly associated with overall survival.

Multivariate analysis ([Table 3](#T3){ref-type="table"}) demonstrated that tumor grade was an independent poor prognostic indicator for both recurrence-free and overall survival (P = 0.01 and P = 0.005, respectively). CK19 expression was an independent prognostic predictor for only decreased recurrence-free survival (P = 0.003). When the combined evaluation of arginase-1 and CK19 expressions was used as replacement of CK19 alone or arginase-1 alone, the combination variable was a significant independent predictor of postoperative recurrence (P = 0.002).

###### Multivariate Predictors for RFS and OS in Patients With HCC

  Variables           RFS     OS                                                     
  ------------------- ------- -------- -------- --------- -------- -------- -------- -----------
  AFP                 1.629   0.613    0.7506   0.21      2.256    0.677    7.512    0.05856
  Tumor grade         2.744   1.2402   6.072    0.01      5.9432   1.7066   20.696   0.00512
  Vascular invasion   1.456   0.581    3.646    0.422     1.5537   0.4325   5.582    0.49947
  TNM stage III/IV    1.848   0.8172   4.178    0.14      1.495    0.4721   4.734    0.49414
  CK19                3.626   1.728    7.608    0.003     0.4419   0.122    1.601    0.21372
  Arginase-1/CK19     3.125   1.5149   6.447    0.002\*   0.4511   0.1241   1.639    0.22655\*

HCC: hepatocellular carcinoma; OS: overall survival; RFS, recurrence-free survival; HR: hazard ratio; CI: confidence interval; TNM: tumor-node-metastasis; AFP: alpha-fetoprotein; CK19: cytokeratin 19. \*This P value was obtained from replacement of single variable CK19 to the combined variable in the Cox regression analysis.

Of the 112 total patients in our study, 30 (12 CK19-positive and 15 CK19-negative) developed recurrence during the follow-up period. The overall median time to recurrence was 12 months, while the overall median time to death was 12.5 months. Recurrence occurred in 23 patients with high arginase-1 HCC expression, and median time to recurrence was lower in patients with high arginase-1 HCC expression (12 months) than in those with low arginase-1 HCC expression (19 months). On the other hand, the median time to recurrence in patients with CK19-positive HCC was 10.5 months compared to 14.5 months in those with CK19-negative HCC.

Discussion {#s4}
==========

In the normal liver, hepatocytes express the cytokeratin family members CK8 and CK18 as well as a variety of hepatocytic markers, such as HepPar-1 and arginase-1; in contrast, CK19 is expressed in the cholangiocytes and hepatic progenitor cells \[[@R14]\]. HCC is typically derived from malignant transformation of benign hepatocytes and is characteristically associated with high expression of arginase-1. However, CK19 expression has been reported in HCC derived from hepatic stem cells \[[@R11], [@R14]\]. Tumor grade, tumor size, tumor number, vascular invasion and TNM staging have all been used as predictors of recurrence-free survival. Favorable outcomes have been observed in patients who undergo curative surgery but recurrence of HCC can occur in patients with excellent tumor characteristics, such as well-differentiated tumors without vascular invasion. Thus, it is imperative that additional tumor markers for prediction of recurrence be identified.

CK19 expression has been associated with early recurrence \[[@R12], [@R16]\], but the prognostic significance requires further evaluation. Knowledge on the clinicopathologic and prognostic importance of arginase-1 in HCC is very limited currently. Furthermore, the combination of arginase-1 and CK19 as prognostic markers has never been explored. In this study, we evaluated and addressed these issues. The prognostic significance of arginase-1 has only been analyzed in one study to date. Mao and colleagues \[[@R08]\] showed that high arginase-1 expression was associated with higher recurrence-free and overall survival. However, 98% of the HCC tumors in that study showed arginase-1 expression, as detected by immunostaining with a polyclonal antibody, which may have increased nonspecific staining, making clear stratification of arginase-1 expression hard to interpret. In our study described herein, we used a highly specific monoclonal antibody that greatly improved detection of arginase-1. In our patients with low arginase expression, immunostaining for arginase-1 was either absent or had weak or focal staining in less than 15% of the tumor cells. Our patients with high arginase-1 expression had a shorter median time to recurrence than the patients with low arginase-1 expression. Interestingly, the patients with high arginase-1 expression also had higher hazard ratios (HRs) for recurrence-free survival (HR: 1.904, P = 0.12) and overall survival (HR: 3.489, P = 0.14), although the values did not reach the level for statistical significance. In addition, we found the high arginase-1 expression to be associated with decreased recurrence-free survival in patients with vascular invasion and advanced TNM stage, suggesting its potential as a predictor for recurrence in these patients. The findings of this study are not surprising because the majority of HCC tumors express arginase-1, suggesting that it will be unusual to be identified as a good prognostic parameter in use alone. Limitations as to why statistical significance was not achieved include the small sample size. Secondly there was an uneven patient population into high and low arginase populations. This is attributed to the sensitivity and specificity of our monoclonal arginase-1 antibody which is very efficient in the stratification of arginase-1 based on expression. Very few HCC tumors have low expression levels of arginase-1. These reasons might account, at least in part, for the imperfect results. Large-scale studies appear warranted for the evaluation of arginase-1 in HCC.

On the other hand, CK19 was found to be significantly associated with decreased recurrence-free survival (both in the univariate and multivariate analyses). We further showed that the combined evaluation of arginase-1 and CK19 was more effectively associated with lower recurrence-free survival in univariate analysis than arginase-1 alone ([Table 2](#T2){ref-type="table"}). Thus, CK19 might increase the prognostic power of arginase-1 in HCC patients, a notion which is further supported by the confirmatory univariate and multivariate analyses. Examination of the data suggests that this may be due to exclusion of arginase-1 low expression in the tumors that were CK19-positive. Furthermore, combinations of arginase-1 and CK19 with other significant clinicopathologic factors were all associated with decreased recurrence-free survival. Although CK19 and CK19/arginase-1 positive tumors were associated with decreased recurrence-free survival, they both did not achieve significant poor overall survival. We believe that this is due to small sample size which indicates that the analysis of overall survival has lower power when compared to that of recurrence-free survival. This is reflected in the HR which is slightly greater than 1 in both clinical factors, and perhaps in a larger study with a longer follow-up period, this upward trend will become significant. Secondly, the wide 95% confidence interval supports this theory. Furthermore, the smaller effect of CK19 and CK/arginase-1 on overall survival may be due to the fact that a median overall survival 2 - 4 times longer than recurrence-free survival is required for one to see any meaningful statistical significance. Lastly, the overall survival of the patients may be influenced by competing risk factors of death and possible treatment effect. Determining the true prognostic value of CK19 and CK19/arginase-1 in association with overall survival will require further evaluation in large clinical studies.

The study of arginase-1 as a prognostic factor is very important. Arginase is responsible for the conversion of arginine to urea and L-ornithine in the urea cycle. Arginine, a semi-essential amino acid, has been shown to be important for the proliferation of myriad human cancers, including HCC \[[@R17]\]. Arginine depletion inhibits the growth of human HCC through cell cycle arrest and apoptosis. Such arginine depletion in HCC can be achieved either by the use of pegylated arginine deaminase \[[@R18]\] or human recombinant arginase \[[@R19]\]. HCC is thought to be dependent on exogenous arginine for growth because the cells generally cannot internally synthesize arginine and are, therefore, auxotrophic for arginine. The mechanism of tumor inhibition through arginine depletion in HCC is thought to be related to the lack of argininosuccinate synthetase, the rate-limiting enzyme in arginine synthesis. Although arginine deprivation shows promising results in *in vitro* and *in vivo* studies, clear clinical benefits are yet to be demonstrated in human clinical trials in patients with advanced HCC \[[@R20]-[@R22]\]. Interestingly, since arginase is highly expressed in HCC, it would be difficult to believe that it is associated with good prognosis. Indeed, arginase expression was found by western blotting to be significantly higher in HCC compared to normal and cirrhotic liver tissues \[[@R23]\]. Chrzanowska and coworkers \[[@R24], [@R25]\] showed high serum arginase activity in patients with HCC, which drastically decreased following surgery; therefore, the authors suggested a role for arginase in monitoring patients with HCC following hepatectomy which correlates well with our hypothesis.

These findings collectively suggest that arginase activity may be involved in the tumorigenesis of HCC. Because the mechanism of the metabolism of arginase in HCC is not clearly understood and the demonstration that arginase expression is not associated with good prognosis, it is important to consider that there may be other associated variables that may not favor arginase as a feasible target for arginine depletion (or function deprivation). It may be possible that arginase expression in combination with other clinicopathologic parameters such as CK19 expression, vascular invasion and advanced tumor stage facilitates tumor progression which results in tumor recurrence. Thus, the exact prognostic role of arginase-1 should be subjected to further validation in large-scale studies.

In conclusion, our data indicate that combination of CK19 with arginase-1 might have higher prognostic efficiency than arginase-1 or CK19 alone in patients with HCC who have undergone curative hepatectomy in the determination of tumor recurrence. However, this approach requires further validation and may prove to be beneficial in prognostic stratification of patients with HCCs, helping to achieve better clinical outcome.
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